Evidence map›Paper›PMID 41282185›Full record

ArticleResearch square2025

Uncovering a role for METTL13 in malignant transformation of human hematopoietic stem cells and in the progression of pediatric leukemia.

Sabina Enlund, Chae-Eun Lim, Isabella Hoang, Sonali Joshi, Amanda Ramilo Amor, Cecilia Thomsson, Indranil Sinha, Shahrzad Shirazi Fard, Anna Nilsson, Ola Hermanson and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sabina EnlundDeparment of Women's and Children's Health, Division of Pediatric Oncology and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden.
Chae-Eun LimDivision of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA, Moores Cancer Center, La Jolla, CA 92037, USA.
Isabella HoangDivision of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA, Moores Cancer Center, La Jolla, CA 92037, USA.
Sonali JoshiDivision of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA, Moores Cancer Center, La Jolla, CA 92037, USA.
Amanda Ramilo AmorDeparment of Women's and Children's Health, Division of Pediatric Oncology and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden.
Cecilia ThomssonDeparment of Women's and Children's Health, Division of Pediatric Oncology and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden.
Indranil SinhaDepartment of Laboratory Medicine, Karolinska Institutet, 141 52 Huddinge, Sweden.ORCID 0000-0002-2513-5927
Shahrzad Shirazi FardDeparment of Women's and Children's Health, Division of Pediatric Oncology and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden.
Anna NilssonDeparment of Women's and Children's Health, Division of Pediatric Oncology and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden.
Ola HermansonDepartment of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0001-9320-7921
Qingfei JiangDivision of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA, Moores Cancer Center, La Jolla, CA 92037, USA.
Frida HolmDepartment of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.

Funding

Elucidate the Role of RNA Editing in Acute T-cell Lymphoblastic Leukemia Initiating CellsR01CA282792 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Qingfei Jiang · 2024 to 2026
$1.4M
Profiling Epitranscriptomic RNA editing in Pediatric CancerR03CA287274 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JIANG, QINGFEI · 2024 to 2025
$316k
NCI NIH HHS R01 CA282792NCI NIH HHS R03 CA287274
6 · The paper itself

Abstract

Post-transcriptional RNA modifications, such as N6-methyladenosine (m6A) methylation and adenosine to inosine (A-to-I) editing, are critical regulators of hematopoietic stem cell (HSC) self-renewal and differentiation, yet their precise contributions to malignant transformation are not fully elucidated. In this study, we uncovered the epitranscriptomic landscape caused by knockdown of genes from the methyltransferase (METTL)-family in hematopoietic stem and progenitor cells (HSPCs). We identified both converging and distinct roles of METTL3 and METTL14, known members of the m6A writer complex, as well as orphan gene METTL13. Notably, METTL13 was uniquely upregulated by adenosine deaminase acting on RNA 1 (ADAR1) overexpression, while other METTL genes were downregulated. Knockdown of METTL13 altered the expression of multiple genes involved in oncogenic development in HSPCs. Furthermore, METTL13 was associated with a high-risk profile in pediatric T-cell acute lymphoblastic leukemia (T-ALL), and functional studies confirmed that METTL13 is required for T-ALL cell proliferation and survival both

Identifiers

PMID41282185
PMCPMC12633491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.